Bruce Mixan

1.6k total citations · 1 hit paper
14 papers, 1.2k citations indexed

About

Bruce Mixan is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Oncology. According to data from OpenAlex, Bruce Mixan has authored 14 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Immunology and 5 papers in Oncology. Recurrent topics in Bruce Mixan's work include Monoclonal and Polyclonal Antibodies Research (9 papers), Toxin Mechanisms and Immunotoxins (6 papers) and HER2/EGFR in Cancer Research (4 papers). Bruce Mixan is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), Toxin Mechanisms and Immunotoxins (6 papers) and HER2/EGFR in Cancer Research (4 papers). Bruce Mixan collaborates with scholars based in United States and Germany. Bruce Mixan's co-authors include Alan F. Wahl, Clay B. Siegall, Dana F. Chace, Peter D. Senter, Kerry Klussman, Charles G. Cerveny, Che‐Leung Law, Kristine A. Gordon, Joseph A. Francisco and Damon L. Meyer and has published in prestigious journals such as Journal of Biological Chemistry, Blood and The Journal of Immunology.

In The Last Decade

Bruce Mixan

14 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

2003 668 citations Joseph A. Francisco, Charles G. Cerveny et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruce Mixan United States	12	608	489	372	286	285	14	1.2k
Lori Westendorf United States	14	728 1.2×	646 1.3×	522 1.4×	229 0.8×	76 0.3×	29	1.2k
David V. Gold United States	29	883 1.5×	637 1.3×	936 2.5×	431 1.5×	107 0.4×	67	2.0k
Hermine Schlagbauer‐Wadl Austria	16	820 1.3×	99 0.2×	1.2k 3.3×	299 1.0×	85 0.3×	19	1.8k
Matthew J. Bernett United States	16	464 0.8×	400 0.8×	418 1.1×	366 1.3×	103 0.4×	40	1.2k
Guorong Luo China	15	315 0.5×	366 0.7×	812 2.2×	860 3.0×	74 0.3×	27	1.4k
Maureen Dougher United States	14	587 1.0×	433 0.9×	345 0.9×	132 0.5×	223 0.8×	24	1.0k
Mariana Nacht United States	17	441 0.7×	108 0.2×	1.0k 2.7×	268 0.9×	171 0.6×	27	1.5k
Enrico L. DiGiammarino United States	18	887 1.5×	168 0.3×	972 2.6×	206 0.7×	29 0.1×	30	1.5k
Gerhard Niederfellner Germany	22	847 1.4×	710 1.5×	769 2.1×	519 1.8×	302 1.1×	36	1.9k
Martha E. Anderson United States	18	1.4k 2.2×	1.1k 2.3×	865 2.3×	288 1.0×	60 0.2×	38	2.1k

Countries citing papers authored by Bruce Mixan

Since Specialization

Citations

This map shows the geographic impact of Bruce Mixan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Mixan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Mixan more than expected).

Fields of papers citing papers by Bruce Mixan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce Mixan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Mixan. The network helps show where Bruce Mixan may publish in the future.

Co-authorship network of co-authors of Bruce Mixan

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce Mixan. A scholar is included among the top collaborators of Bruce Mixan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce Mixan. Bruce Mixan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Law, Che‐Leung, Kristine A. Gordon, J.M. Collier, et al.. (2005). Preclinical Antilymphoma Activity of a Humanized Anti-CD40 Monoclonal Antibody, SGN-40. Cancer Research. 65(18). 8331–8338. 99 indexed citations

Law, Che‐Leung, Charles G. Cerveny, Kristine A. Gordon, et al.. (2004). Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates. Clinical Cancer Research. 10(23). 7842–7851. 84 indexed citations

Klussman, Kerry, Bruce Mixan, Charles G. Cerveny, et al.. (2004). Secondary mAb−vcMMAE Conjugates Are Highly Sensitive Reporters of Antibody Internalization via the Lysosome Pathway. Bioconjugate Chemistry. 15(4). 765–773. 17 indexed citations

Francisco, Joseph A., Charles G. Cerveny, Damon L. Meyer, et al.. (2003). cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 102(4). 1458–1465. 668 indexed citations breakdown →

Wahl, Alan F., Karen Donaldson, Bruce Mixan, Pamela A. Trail, & Clay B. Siegall. (2001). Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. International Journal of Cancer. 93(4). 590–600. 30 indexed citations

Senter, Peter D., et al.. (2001). Identification and Activities of Human Carboxylesterases for the Activation of CPT-11, a Clinically Approved Anticancer Drug. Bioconjugate Chemistry. 12(6). 1074–1080. 80 indexed citations

Mixan, Bruce, et al.. (1998). Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity. Oncogene. 16(9). 1209–1215. 7 indexed citations

Siegall, Clay B., Helen G. Haggerty, Garvin L. Warner, et al.. (1997). Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy. The Journal of Immunology. 159(10). 5168–5173. 26 indexed citations

Siegall, Clay B., Denny Liggitt, Dana F. Chace, et al.. (1997). Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.. PubMed. 3(3). 339–45. 36 indexed citations

10.

Francisco, Joseph A., Susan L. Gawlak, Michael M. Miller, et al.. (1997). Expression and Characterization of Bryodin 1 and a Bryodin 1-Based Single-Chain Immunotoxin from Tobacco Cell Culture. Bioconjugate Chemistry. 8(5). 708–713. 41 indexed citations

11.

Bacus, Sarah, D Chin, Clay B. Siegall, et al.. (1995). HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein. Journal of Biological Chemistry. 270(13). 7625–7630. 20 indexed citations

12.

Siegall, Clay B., E Wolff, Susan L. Gawlak, et al.. (1995). Immunotoxins as cancer chemotherapeutic agents. Drug Development Research. 34(2). 210–219. 10 indexed citations

13.

Siegall, Clay B., Dana F. Chace, Bruce Mixan, et al.. (1994). In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.. The Journal of Immunology. 152(5). 2377–2384. 36 indexed citations

14.

Siegall, Clay B., Susan L. Gawlak, Dana F. Chace, et al.. (1994). Characterization of Ribosome-Inactivating Proteins Isolated from Bryonia dioica and Their Utility as Carcinoma-Reactive Immunoconjugates. Bioconjugate Chemistry. 5(5). 423–429. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact